Sept 19 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved a new formulation of Merck's (MRK.N), opens new tab blockbuster cancer therapy Keytruda that can be ...
Merck MRK is focusing on driving its long-term growth with its new products and a promising set of pipeline candidates as its blockbuster PD-L1 inhibitor, Keytruda, faces patent expiration in 2028.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results